000			02393 a2200673 4500
005			20250517151714.0
264		0	_c20170911
008			201709s 0 0 eng d
022			_a1097-0142
024	7		_a10.1002/cncr.30736 _2doi
040			_aNLM _beng _cNLM
100	1		_aMoore, Kathleen N
245	0	0	_aPhase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. _h[electronic resource]
260			_bCancer _cAug 2017
300			_a3080-3087 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Journal Article
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aCarcinoma, Non-Small-Cell Lung _xdrug therapy
650	0	4	_aCarcinoma, Ovarian Epithelial
650	0	4	_aCarcinoma, Renal Cell _xdrug therapy
650	0	4	_aDiarrhea _xchemically induced
650	0	4	_aDisease Progression
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aEndometrial Neoplasms _xdrug therapy
650	0	4	_aFatigue _xchemically induced
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aHypophosphatemia _xchemically induced
650	0	4	_aImmunoconjugates _xtherapeutic use
650	0	4	_aKeratitis _xchemically induced
650	0	4	_aKidney Neoplasms _xdrug therapy
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMaximum Tolerated Dose
650	0	4	_aMaytansine _xanalogs & derivatives
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aNeoplasms, Glandular and Epithelial _xdrug therapy
650	0	4	_aOvarian Neoplasms _xdrug therapy
650	0	4	_aVision Disorders _xchemically induced
700	1		_aBorghaei, Hossein
700	1		_aO'Malley, David M
700	1		_aJeong, Woondong
700	1		_aSeward, Shelly M
700	1		_aBauer, Todd M
700	1		_aPerez, Raymond P
700	1		_aMatulonis, Ursula A
700	1		_aRunning, Kelli L
700	1		_aZhang, Xiaoyan
700	1		_aPonte, Jose F
700	1		_aRuiz-Soto, Rodrigo
700	1		_aBirrer, Michael J
773	0		_tCancer _gvol. 123 _gno. 16 _gp. 3080-3087
856	4	0	_uhttps://doi.org/10.1002/cncr.30736 _zAvailable from publisher's website
999			_c27111546 _d27111546